360 related articles for article (PubMed ID: 10599792)
1. Rapidly progressive, predominantly motor Guillain-Barré syndrome with anti-GalNAc-GD1a antibodies.
Ang CW; Yuki N; Jacobs BC; Koga M; Van Doorn PA; Schmitz PI; Van Der Meché FG
Neurology; 1999 Dec; 53(9):2122-7. PubMed ID: 10599792
[TBL] [Abstract][Full Text] [Related]
2. Spectrum of neurological diseases associated with antibodies to minor gangliosides GM1b and GalNAc-GD1a.
Tatsumoto M; Koga M; Gilbert M; Odaka M; Hirata K; Kuwabara S; Yuki N
J Neuroimmunol; 2006 Aug; 177(1-2):201-8. PubMed ID: 16844234
[TBL] [Abstract][Full Text] [Related]
3. Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.
Schessl J; Koga M; Funakoshi K; Kirschner J; Muellges W; Weishaupt A; Gold R; Korinthenberg R
Arch Dis Child; 2007 Jan; 92(1):48-52. PubMed ID: 16920757
[TBL] [Abstract][Full Text] [Related]
4. [Antiganglioside autoantibody profiles in Guillain-Barré syndrome].
Caudie C; Vial C; Bancel J; Petiot P; Antoine JC; Gonnaud PM
Ann Biol Clin (Paris); 2002; 60(5):589-97. PubMed ID: 12368145
[TBL] [Abstract][Full Text] [Related]
5. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan.
Ogawara K; Kuwabara S; Mori M; Hattori T; Koga M; Yuki N
Ann Neurol; 2000 Oct; 48(4):624-31. PubMed ID: 11026446
[TBL] [Abstract][Full Text] [Related]
6. An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain-Barré syndrome with reversible conduction failure.
Ogawa G; Kaida K; Kuwahara M; Kimura F; Kamakura K; Kusunoki S
J Neuroimmunol; 2013 Jan; 254(1-2):141-5. PubMed ID: 23000056
[TBL] [Abstract][Full Text] [Related]
7. Ataxic Guillain-Barré syndrome associated with anti-GM1b and anti-GalNAc-GD1a antibodies.
Odaka M; Yuki N; Tatsumoto M; Tateno M; Hirata K
J Neurol; 2004 Jan; 251(1):24-9. PubMed ID: 14999485
[TBL] [Abstract][Full Text] [Related]
8. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance.
Hao Q; Saida T; Yoshino H; Kuroki S; Nukina M; Saida K
Ann Neurol; 1999 Jun; 45(6):758-68. PubMed ID: 10360768
[TBL] [Abstract][Full Text] [Related]
9. GM1/GalNAc-GD1a complex: a target for pure motor Guillain-Barre syndrome.
Kaida K; Sonoo M; Ogawa G; Kamakura K; Ueda-Sada M; Arita M; Motoyoshi K; Kusunoki S
Neurology; 2008 Nov; 71(21):1683-90. PubMed ID: 19015484
[TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome with antibody to a ganglioside, N-acetylgalactosaminyl GD1a.
Kaida K; Kusunoki S; Kamakura K; Motoyoshi K; Kanazawa I
Brain; 2000 Jan; 123 ( Pt 1)():116-24. PubMed ID: 10611126
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of neuropathies in a group of patients associated with anti-GalNAc-GD1a antibody].
Tatsumoto M; Odaka M; Koga M; Hirata K; Yuki N
Rinsho Shinkeigaku; 2004 Aug; 44(8):508-12. PubMed ID: 15471085
[TBL] [Abstract][Full Text] [Related]
12. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barré syndrome.
Koga M; Takahashi M; Masuda M; Hirata K; Yuki N
Neurology; 2005 Nov; 65(9):1376-81. PubMed ID: 16162859
[TBL] [Abstract][Full Text] [Related]
13. Ganglioside mimicry as a cause of Guillain-Barré syndrome.
Komagamine T; Yuki N
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):391-400. PubMed ID: 16918391
[TBL] [Abstract][Full Text] [Related]
14. Anti-ganglioside complex antibodies associated with severe disability in GBS.
Kaida K; Morita D; Kanzaki M; Kamakura K; Motoyoshi K; Hirakawa M; Kusunoki S
J Neuroimmunol; 2007 Jan; 182(1-2):212-8. PubMed ID: 17113161
[TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome with IgM antibody to the ganglioside GalNAc-GD1a.
Kaida K; Kusunoki S; Kamakura K; Motoyoshi K; Kanazawa I
J Neuroimmunol; 2001 Feb; 113(2):260-7. PubMed ID: 11164910
[TBL] [Abstract][Full Text] [Related]
16. Differential immune response to gangliosides in Guillain-Barré syndrome patients from Japan and The Netherlands.
Ang CW; Koga M; Jacobs BC; Yuki N; van der Meché FG; van Doorn PA
J Neuroimmunol; 2001 Dec; 121(1-2):83-7. PubMed ID: 11730944
[TBL] [Abstract][Full Text] [Related]
17. [Case of pure motor Guillain-Barré syndrome with motor conduction block and anti-GM1/GalNAc-GD1a antibody].
Ogawa G; Kaida K; Shiozaki Y; Araki M; Kimura F; Kamakura K
Rinsho Shinkeigaku; 2009 Aug; 49(8):488-92. PubMed ID: 19827599
[TBL] [Abstract][Full Text] [Related]
18. Temporal profile of anti-ganglioside antibodies and their relation to clinical parameters and treatment in Guillain-Barré syndrome.
Press R; Matá S; Lolli F; Zhu J; Andersson T; Link H
J Neurol Sci; 2001 Sep; 190(1-2):41-7. PubMed ID: 11574105
[TBL] [Abstract][Full Text] [Related]
19. Antibody to GalNAc-GD1a and GalNAc-GM1b in Guillain-Barré syndrome subsequent to Campylobacter jejuni enteritis.
Yuki N; Taki T; Handa S
J Neuroimmunol; 1996 Dec; 71(1-2):155-61. PubMed ID: 8982115
[TBL] [Abstract][Full Text] [Related]
20. Close association of IgA anti-ganglioside antibodies with antecedent Campylobacter jejuni infection in Guillain-Barré and Fisher's syndromes.
Koga M; Yuki N; Takahashi M; Saito K; Hirata K
J Neuroimmunol; 1998 Jan; 81(1-2):138-43. PubMed ID: 9521615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
